F. Dalenc

Statistics

Publications

Citations

807

H-Index

Active since

2021

Affiliations

UCSF Helen Diller Family Comprehensive Cancer Center(Current)

The Christie NHS Foundation Trust

Vall d'Hebron Hospital Universitari

Memorial Sloan Kettering Cancer Center

Institute of Oncology NN Petrov

F. Dalenc is an author at UCSF Helen Diller Family Comprehensive Cancer Center specializing in oncology, metastatic breast cancer treatment, and pharmacology.

Publications per year

2021–2024

Publications

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

David Miles, Joseph Gligorov, Fabrice André et al. · Annals of Oncology · 2021 · 729 citations · Full text

Medicine, Oncology, Pharmacology +17

LBA76 Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC)

Hope S. Rugo, A. Bardia, F. Marmé et al. · Annals of Oncology · 2022 · 57 citations · Full text

Medicine, Oncology, Pharmacology +12

Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study

H.S. Rugo, M. Oliveira, Sacha J. Howell et al. · ESMO Open · 2024 · 21 citations · Full text

Pharmacy, Oncology, Pharmacology +17

1–3 of 3